louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02958514: Efficacy Comparison of Two Kinds of Treatment in Treating Dry Eye Caused by Meibomian Gland Dysfunction
Official title: Efficacy Comparison of Two Kinds of Treatment in Treating Dry Eye Caused by Meibomian Gland Dysfunction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dry Eye Syndrome
Keywords: IPL
MGD
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2016-11-08
Enrollment: 20
Sex: ALL
Minimum age (years): 26
Maximum age (years): 78
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate the efficacy of intense pulsed light in treating dry eye caused by meibomian gland dysfunction and make a comparison between the traditional treatment.


Eligibility criteria: Inclusion Criteria:

* patients with dry eye syndrome and diagnosed as MGD

Exclusion Criteria:

* an infection or inflammatory disease;
* ocular surgical history with in the last 3 months
* SGOGREN SYNDROME

Primary outcomes:
measure: Ocular Surface Disease Index (OSDI)
timeFrame: through study completion,an average of 6 months
Secondary outcomes:
measure: The concentrations of inflammatory cytokines such as IL-1、IL-6 and IL-8
timeFrame: through study completion,an average of 6 months
measure: breakup time of tear film （BUT）
timeFrame: through study completion,an average of 6 months
measure: Corneal Fluorescein Stain(CFS)
timeFrame: through study completion,an average of 6 months
measure: Eyelid ester discharge ability score
timeFrame: through study completion,an average of 6 months
measure: Eyelid ester trait ratings
timeFrame: through study completion,an average of 6 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01974414: Cedar Honey in Oral Lichen Planus
Official title: Cedar Honey in Treatment of Oral Lichen Planus: a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Erosive and Atrophic Oral Lichen Planus
Keywords: oral lichen planus
cedar honey
atrophic
erosive
pain
treatment
clinical trial
Lead sponsor: Mashhad University of Medical Sciences
Sponsor class: OTHER
First posted: 2013-11-01
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study aimed to evaluate the effect of cedar honey in treatment of erosive and atrophic oral lichen planus ( a common oral problem).


Eligibility criteria: Inclusion Criteria:

1. clinically and histopathologically confirmed oral lichen planus without dysplasia in histopathologic evaluation
2. Severity of pain≥2 (VAS score)
3. Severity of lesions≥2 (tong prasom criteria)
4. absence of any treatment in the last month
5. absence of kidney or liver diseases( due to systemic administration of fluconazole to both groups)

Exclusion Criteria:

1. evidence of lichenoid reaction in clinical or histopathologic assessment
2. loss of follow up
3. pregnant patients
4. diabetic patients
5. any other mucosal disease
6. any severe systemic disease
7. patients who refuse doctor's advice
8. any unexpected adverse effect of honey

Primary outcomes:
measure: severity of lesions
timeFrame: 4 weeks
Secondary outcomes:
measure: size of lesions
timeFrame: 4 weeks
Other outcomes:
measure: pain of lesions
timeFrame: 4 weeks
Locations:
city: Mashhad
country: Iran, Islamic Republic of
facility: Oral Medicine Department of Mashhad dental School,Oral and Maxillofacial diseases research center
state: Khorasan Razavi
Study officials:
affiliation: Mashhad University of Medical Sciences
name: Majid Sanatkhani, Assistant Professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT03049514: Study of Arterial Recanalization of the Central Retinal Artery Occlusions
Official title: Study of Arterial Recanalization of the Central Retinal Artery Occlusions
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Central Retinal Artery Occlusion
Keywords: Thrombolysis
Recanalization
Dynamic retinal angiography
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2017-02-10
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients referred for an central retinal artery occlusion

Brief summary: Central retinal artery occlusions (CRAO) are the equivalent of an ischemic stroke (IS) at the retinal level. They share the same risk factors and common pathology. Their incidence is lower (8.5 / 100,000) and the functional prognosis is unfavorable in 80% of cases with visual acuity (VA) \<1/10. The diagnosis of an CRAO is clinically based on the sudden occurrence of a decrease in deep visual acuity with fundamentally signs of reactive ischemia. There is no data on early retinal arterial recanalization after CRAO, nor on the relationship between early recanalization (spontaneous or post-thrombolysis) and visual prognosis.


Eligibility criteria: Inclusion Criteria:

* Central Retinal Artery Occlusion ≤ 24 hours

Exclusion Criteria:

* Retinal Dynamic angiography not performed within 48 hours of onset of symptoms
* Occlusion of a branch of the central retinal artery

Primary outcomes:
measure: Dynamic retinal angiography data at 24 hours (+/- 24 hours)
timeFrame: 24 hours (+/- 24 hours) following the beginning of symptoms
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Fondation ophtalmique Adolphe de Rothschild
Study officials:
affiliation: Fondation A de Rothschild
name: Michaël Obadia, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04343014: Tongue Root Retractor For Fibroscopic Intubation
Official title: Effects of Tongue Root Retractor for Fibroscopic Intubation: a Feasibility Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Airway Management
Keywords: fibreoptic intubation
Lead sponsor: The First Affiliated Hospital with Nanjing Medical University
Sponsor class: OTHER
First posted: 2020-04-13
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients admit to the operation rooms of First Affiliated Hospital of Nanjing Medical University and requiring endotracheal intubation for general anesthesia will be enrolled in this case controlled study.

Patients 1) aged 18 to 70 years; 2) ASA graded I\~II class; 3) general anesthesia should be performed under endotracheal intubation, will be included from this study. Patients 1) with organ transplant operations; 2) with thoracic and cardiac vascular surgery; 3) with severe heart or lung disease; 4) BMI over 35kg/m2, will be excluded from this study.

The primary aim is to compare airway clearance for fibreoptic tracheal intubation in each patient position. Secondary outcomes include times to view the vocal cord and carina, the time for tube advancement through the vocal cords, as well as the total time to achieve tracheal intubation.Two anesthesiologists with 5 years of experience in conventional endotracheal intubation and trained for fibreoptic intubation will perform the maneuvers.


Eligibility criteria: Inclusion Criteria:

* aged 18 to 70 years
* ASA graded I\~II class
* scheduled for elective surgery requiring orotracheal intubation

Exclusion Criteria:

* with organ transplant operations
* with thoracic and cardiac vascular surgery
* with severe cadiac or pulmonary disease
* BMI over 35kg/m2

Primary outcomes:
measure: Feasibility of intubation.
timeFrame: From start of intubation to successfully intubated (the endotracheal tube enters the trachea and the cuff is inflated), usually within 3 minutes.
Secondary outcomes:
measure: Epiglottis level
timeFrame: within 30 seconds after the beginning of fibroscopy
measure: Carina time
timeFrame: within 90 seconds
measure: Successful Intubation on 1st Attemp
timeFrame: from start of first intubation to end of first intubation attempt
measure: Number of attempts for tube advancement
timeFrame: within 120 seconds
Other outcomes:
Locations:
city: Nanjing
country: China
facility: The First Affiliated Hospital of Nanjing Medical University
state: Jiangsu
Study officials:
affiliation: The First Affiliated Hospital with Nanjing Medical University
name: Zhengnian Ding, M.D.
role: STUDY_CHAIR
affiliation: The First Affiliated Hospital with Nanjing Medical University
name: Xiaofei Cao, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: The First Affiliated Hospital with Nanjing Medical University
name: Junbei Wu, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04586114: Effect of Corticosteroid Treatment on Prognosis in ARDS Secondary to Covid-19
Official title: Effect of Early Corticosteroid Therapy on Mortality in Patient With Acute Respiratory Distress Syndrome Secondary to Covid-19
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Respiratory Distress Syndrome Secondary to Covid-19
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2020-10-14
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient more than 18 years old hospitalized in ICU from 01/03/2020 to 30/04/2020 with acute respiratory distress syndrome secondary to Sars-Cov-2 infection without any corticosteroid treatment before admission, excluding patients with mechanical ventilation more than 48 hours before admission and patients transferred to other ICU.

Brief summary: Study conducted on hospitalized patient in critical ill units in Nancy and Metz to evaluate if early corticosteroid treatment in first seven days after admission improve patients outcome in Acute Respiratory Distress Syndrome secondary to Covid-19 compared to later corticosteroid therapy or no treatment. Also comparison of acquired infection with or without corticosteroid treatment during hospitalisation.


Eligibility criteria: Inclusion Criteria:

* ICU hospitalized with acute respiratory distress syndrome secondary to Sars-Cov-2 infection diagnosed by PCR test
* Hospitalized from 01/03/2020 to 30/04/2020

Exclusion Criteria:

* Mechanical ventilation more than 48 hours at admission
* Transfert to another ICU during stay for bed management
* Corticosteroid treatment at admission

Primary outcomes:
measure: Mortality in ICU
timeFrame: within ICU stay, on average 15 days
Secondary outcomes:
measure: Mortality d28
timeFrame: 28 days
measure: acquired infections incidence
timeFrame: 28 days
measure: antibiotics duration
timeFrame: 28 days
measure: mechanical ventilation duration
timeFrame: 28 days
Other outcomes:
Locations:
city: Nancy
country: France
facility: Hopital Central, Service de Reanimation Medicale
Study officials:
affiliation: Central Hospital, Nancy, France
name: Sebastien GIBOT
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05945914: Incorporating Robotic Surgery in Both Mastectomy and DIEP Flap Reconstruction
Official title: Oncoplastic Entirely Robot-Assisted Approach (OPERA) - Incorporating Robotic Surgery in Both Mastectomy and DIEP Flap Reconstruction
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Breast Reconstruction
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
First posted: 2023-07-14
Enrollment: 9
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with unilateral breast cancer received robotic-assisted mastectomy and robotic assisted free DIEP flap harvest for breast reconstruction

Brief summary: A prospective study will be conducted to assess the outcomes of patients who underwent concurrent robotic-assisted mastectomy and robotic-assisted free DIEP flap harvest for breast reconstruction between March 2020 and June 25, 2023. Demographic data, including age, body mass index (BMI), and medical history, were collected, along with surgical time and perioperative parameters. The incidence of acute and chronic complications was documented.


Eligibility criteria: Inclusion Criteria:

* Patients with unilateral breast cancer received robotic-assisted mastectomy and robotic assisted free DIEP flap harvest for breast reconstruction

Exclusion Criteria:

* None

Primary outcomes:
measure: Re-open
timeFrame: Post-operative 14 days
measure: Acute complication (< 30 days)
timeFrame: Post-operative 30 days
measure: Chronic complication (> 30 days)
timeFrame: One year after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Taoyuan
country: Taiwan
facility: Chang Gung Memorial Hospital
Study officials:
References:
Clinical trial NCT06521814: Globus Reflect Tether - HUD
Official title: Globus Reflect Tether - Humanitarian Use Device
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Scoliosis Idiopathic
Lead sponsor: Medical University of South Carolina
Sponsor class: OTHER
First posted: 2024-07-26
Enrollment: 20
Sex: ALL
Minimum age (years): 10
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this device is to treat children and adolescents with scoliosis who have growth remaining. In patients with a curvature about the spine, Reflect holds the convexity of the curve in place so that the concavity can grow, thereby harnessing the power of normal spine growth to correct the deformity.

Detailed description: The Globus Reflect scoliosis correction system aims to provide curve correction for scoliosis patients who are still actively growing. Surgical correction is accomplished without spinal fusion, instead utilizing anterior vertebral body tethering. This device received an HDE exemption from the FDA and requires MUSC IRB approval to be used.

Eligibility criteria: Inclusion Criteria:

* Skeletally immature patients that require surgical treatment to obtain and maintain correction of progressive idiopathic scoliosis, with a major Cobb angle of 35 to 60 degrees whose osseous structure is dimensionally adequate to accommodate screw fixation, as determined by radiographic imaging.
* Patients should have failed bracing and/or be intolerant to brace wear.

Exclusion Criteria:

* Pregnancy (current)
* Prior spinal or chest surgery
* MRI abnormalities (including syrinx greater than 4mm, Chiari malformation, or tethered cord)
* Neuromuscular, thoracogenic, cardiogenic scoliosis, or any other non-idiopathic scoliosis
* Associated syndrome, including Marfan Disease or Neurofibromatosis
* Sanders stage greater than 4
* Thoracic curve less than 35 or greater than 60
* Lumbar curve greater than or equal to 35
* Unable or unwilling to firmly commit to returning for required follow-up visits
* Investigator judgement that the subject/family may not be a candidate for the intervention

Primary outcomes:
measure: Cobb angles
timeFrame: Until patients reach the age of 18
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Medical University of South Carolina
name: Robert Murphy
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05119595: PMCF Study on CranioFix®2 System Used for the Fixation of Craniotomized Bone Flaps and Fractures
Official title: Prospective, Single Center PMCF-study on the Performance and Safety of the CranioFix®2 System Used for the Fixation of Craniotomized Bone Flaps and Fractures to the Neurocranium
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Skull Fractures
Keywords: Bone Flap Fixation
Fractures to the Neurocranium
Craniotomized bone flaps
Lead sponsor: Aesculap AG
Sponsor class: INDUSTRY
First posted: 2021-11-15
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients enrolled will be prospectively examined according to the study plan until follow-up examination (depending on routine in clinic).

Brief summary: The CranioFix®2 PMCF study has been set up as an action within the framework of a proactive post-market surveillance system of the manufacturer. The aim of this observational study is to collect systematically and proactively data regarding the performance of CranioFix®2, like adverse events (AEs), handling and cosmetic outcome, under daily clinical practice when used as intended by the manufacturer.


Eligibility criteria: Inclusion Criteria:

* Written informed consent
* Age ≥ 18 years
* Use of CranioFix®2 system according to IfU
* Planned postoperative MRI within clinical routine

Exclusion Criteria:

* Pregnancy
* Patients with hypersensitivity to metals or allergies to the implant materials
* Inflammations in the region of the implant site
* Bone conditions that rule out the application of CranioFix®2 titanium clamps
* Use with artificial cranial bone flaps
* Bone tumors in the area supporting the implant
* Degenerative bone diseases
* Missing dura mater
* Application in the facial skull (viscerocranium) and in the orbital or skull-base region
* Combination of implant components from different manufacturers, i.e. additional use of plates and screws on the same bone fragment

Primary outcomes:
measure: Planarity of Bone Flap After Implantation
timeFrame: Through postoperative course: at discharge (about up to 2 weeks after surgery) and post-operative follow-up (3±2 months after surgery)
Secondary outcomes:
measure: Number of Participants With Adverse Events (Intra- and Postoperative)
timeFrame: through study completion, an average of 3 months
measure: Overall Handling of Instruments for CranioFix®2 System Implantation Documented on a Likert Scale
timeFrame: intraoperative
measure: Stability of the Bone Flap After Fixation
timeFrame: intraoperative, at discharge (about up to 2 weeks after surgery) and post-operative follow-up (3±2 months)
measure: Cosmetic Outcome
timeFrame: intraoperative, at discharge (about up to 2 weeks after surgery) and post-operative follow-up (3±2 months)
Other outcomes:
Locations:
city: Stuttgart
country: Germany
facility: Klinikum Stuttgart - Katharinenhospital
Study officials:
References:
Clinical trial NCT00407914: Safety and Effectiveness of Aquamid as Compared to Restylane for the Aesthetic Treatment of Nasolabial Folds
Official title: A Double-Masked, Randomized, Multi-Center, 2-Arm Parallel Study Comparing the Safety and Effectiveness of Aquamid and Restylane for the Aesthetic Treatment of Nasolabial Folds
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Facial Wrinkles
Keywords: wrinkles
soft tissue filler
Aquamid
Lead sponsor: Contura
Sponsor class: INDUSTRY
First posted: 2006-12-05
Enrollment: 315
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the effectiveness of Aquamid and Restylane in aesthetically enhancing nasolabial folds 6 months after treatment and to evaluate the safety of Aquamid through 12 months after treatment.

The study includes an extended follow up to 24 months.


Eligibility criteria: Inclusion Criteria:

* interested on soft tissue augmentation for the nasolabial folds
* moderate to severe nasolabial fold

Exclusion Criteria:

* sensitivity to anesthetics
* allergy to hyaluronic acid
* previous treatment with permanent fillers in the treated area
* recent previous aesthetic procedure in the treatment area
* infected skin areas or autoimmune diseases affecting the skin

Primary outcomes:
measure: Wrinkle Assessment Scale
timeFrame: Baseline, 3, 6, 9, 12 Months
measure: Adverse device effects
timeFrame: continuosly
Secondary outcomes:
measure: Global Aesthetic Improvement Scale
timeFrame: Optimal treatment, 3, 6, 9 and 12 Months
measure: Injection site reactions
timeFrame: After injection
measure: Adverse events
timeFrame: continuosly
Other outcomes:
Locations:
city: White Plains
country: United States
state: New York
Study officials:
affiliation: Contura
name: Silvia Codony
role: STUDY_DIRECTOR
References:
citation: von Buelow S, von Heimburg D, Pallua N. Efficacy and safety of polyacrylamide hydrogel for facial soft-tissue augmentation. Plast Reconstr Surg. 2005 Sep 15;116(4):1137-46; discussion 1147-8. doi: 10.1097/01.prs.0000179349.14392.a4.
Clinical trial NCT01291095: Accelerated Fractionation Radiotherapy (AFRT) Versus Concurrent Chemoradiotherapy (Crt) In Locally Advanced Head And Neck Squamous Cell Carcinoma
Official title: Phase II Randomized Controlled Trial of Accelerated Fractionation Radiotherapy (6 Fractions Per Week) Versus Concurrent Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: HEAD AND NECK CANCER
Lead sponsor: All India Institute of Medical Sciences
Sponsor class: OTHER
First posted: 2011-02-08
Enrollment: 80
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this trial is to compare the accelerated fractionation radiotherapy and concurrent chemo-radiotherapy in locally advanced head and neck squamous cell carcinoma patients in terms of loco-regional control, toxicities and quality of life.

Detailed description: Concurrent chemo-radiotherapy is a common and conventional method of treating locally advanced head and neck squamous cell carcinoma (HNSCC). In locally advanced HNSCC it has been proved to be superior to radiotherapy alone. On the other side accelerated fractionation radiotherapy (AFRT) is a proven practice to improve cure rate in head and neck cancers. Yet it has not been compared with Concurrent Chemoradiotherapy (CRT) in locally advanced HNSCC and hence this study is aiming to compare CRT versus AFRT.

Eligibility criteria: Inclusion Criteria:

1. Age: 20 - 60 years old
2. Karnofsky performance scale score 70 or above
3. Biopsy proven squamous cell carcinomas (SCC) of oropharynx, larynx and hypopharynx
4. TNM stages- Stage III -IVB
5. Informed consent (in prescribed form under institutional guidelines)

Exclusion Criteria:

1. Lack of histopathological proof of malignancy (HNSCC)
2. Doubtful follow-up and/ or non-compliance
3. Previous oncologic therapy with surgery, radiotherapy or chemotherapy
4. Uncontrolled comorbid conditions e.g hypertension, diabetes mellitus, chronic obstructive pulmonary disease, coronary artery disease

Primary outcomes:
measure: TO COMPARE THE LOCO-REGIONAL TUMOR CONTROL RATE BETWEEN AFRT & CRT IN LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMAS.
timeFrame: 5months(2months treatment period followed by 3 months observation)
measure: TO COMPARE THE TOXICITY BETWEEN AFRT AND CRT IN LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMAS
timeFrame: 3 months(2 month treatment periods followed by 1month observation)
Secondary outcomes:
measure: TO COMPARE POST-THERAPY QUALITY OF LIFE BETWEEN AFRT AND CRT IN LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA.
timeFrame: 5months(2months treatment period followed by 3months observation)
Other outcomes:
Locations:
city: New Delhi
country: India
facility: Dr B.R.A.I.R.C.H, ALL INDIA INSTITUTE OF MEDICAL SCIENCES, NEW DELHI
state: Other state
Study officials:
affiliation: ALL INDIA INSTITUTE OF MEDICAL SCIENCES, NEW DELHI, INDIA
name: Dr SUDEEP DAS, MBBS
role: PRINCIPAL_INVESTIGATOR
References: